Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma

INTRODUCTION: YS110, a humanized monoclonal antibody with a high affinity to CD26, exhibited promising antitumor activity and was generally well-tolerated in the phase 1 part of a phase 1 and 2 Japanese trial in patients with malignant pleural mesothelioma (MPM). Here we report the results of the ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakagawa, Kazuhiko, Kijima, Takashi, Okada, Morihito, Morise, Masahiro, Kato, Motoyasu, Hirano, Katsuya, Fujimoto, Nobukazu, Takenoyama, Mitsuhiro, Yokouchi, Hiroshi, Ohe, Yuichiro, Hida, Toyoaki, Aoe, Keisuke, Kishimoto, Takumi, Hirokawa, Masato, Matsuki, Hironori, Kaneko, Yutaro, Yamada, Taketo, Morimoto, Chikao, Takeda, Masayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474437/
https://www.ncbi.nlm.nih.gov/pubmed/34590026
http://dx.doi.org/10.1016/j.jtocrr.2021.100178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474437/
https://www.ncbi.nlm.nih.gov/pubmed/34590026
http://dx.doi.org/10.1016/j.jtocrr.2021.100178

Ejemplares similares